BiondVax advances its growth strategy towards a new pipeline based on innovative VHH antibodies
Retrieved on:
Tuesday, October 19, 2021
BiondVax, Flávio Kenup, Max Planck Institute of Neurobiology, Compugen (Israeli company), Max Planck, Risk, Macular degeneration, Technology, Board of directors, COVID-19, European Investment Bank, Antibody, Psoriatic arthritis, Pleasure, U.S. Securities and Exchange Commission, Neutralizing antibody, Security (finance), Drug development, Coronavirus, Annual report, Infection, BVXV, Board, Molecular oncology, Research, Inhalation, Nasdaq, Psoriasis, CEO, Max Planck Society, Biophysical chemistry, MPG, CMC, Industry, University Medical Center, Asthma, VHH, UMG, Single-domain antibody, Therapy, Company, Pharmaceutical industry, Vaccine
The parties intend to enter into a 5-year strategic research collaboration including an option for BiondVax to license innovative VHH antibodies.
Key Points:
- The parties intend to enter into a 5-year strategic research collaboration including an option for BiondVax to license innovative VHH antibodies.
- Frequently referred to as nanobodies*, VHH antibodies have the potential to serve as therapeutics and diagnostics for many diseases.
- BiondVax will have an exclusive option for an exclusive worldwide license to advance these additional VHH antibodies through preclinical and clinical development, manufacturing, and commercialization.
- Notably, these VHH antibodies can be mass-produced through recombinant protein manufacturing in sites such as BiondVax's state-of-the-art facility in Jerusalem.